Evaluation of physiological alterations of the placenta through analysis of cell-free messenger ribonucleic acid concentrations of angiogenic factors

American Journal of Obstetrics and Gynecology

Volumn 198, Issue 1, 2008, Pages 124.e1-124.e7

  Purwosunu, Yuditiya ^a,b   Sekizawa, Akihiko ^a   Farina, Antonio ^a,c   Wibowo, Noroyono ^b   Koide, Keiko ^a   Okazaki, Shiho ^a   Nakamura, Masamitsu ^a   Okai, Takashi ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b CIPTO MANGUNKUSUMO HOSPITAL   (Indonesia)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

cell free ribonucleic acid; endoglin; preeclampsia; vascular endothelial growth factor; vascular endothelial growth factor receptor 1

Indexed keywords

ANGIOGENIC FACTOR; BIOLOGICAL MARKER; ENDOGLIN; LIVER ENZYME; MESSENGER RNA; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ADOLESCENT; ADULT; ARTICLE; BLOOD SAMPLING; CELL FREE SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HEMOLYSIS; HUMAN; HYPERTENSION; PERIPHERAL CIRCULATION; PHYSIOLOGY; PLACENTA; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; PROTEINURIA; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; THROMBOCYTE COUNT;

EID: 37349090053     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2007.06.079     Document Type: Article

References (39)

1. Sibai B., Dekker G., and Kupferminc M. Pre-eclampsia. Lancet 365 (2005) 785-799
2. Redman C.W., and Sargent I.L. Latest advances in understanding preeclampsia. Science 308 (2005) 1592-1594
3. Gerber H.P., Hillan K.J., Ryan A.M., et al. VEGF is required for growth and survival in neonatal mice. Development 126 (1999) 1149-1159
4. Clark D.E., Smith S.K., Sharkey A.M., and Charnock-Jones D.S. Localization of VEGF and expression of its receptors flt and KDR in human placenta throughout pregnancy. Hum Reprod 11 (1996) 1090-1098
5. He Y., Smith S.K., Day K.A., Clark D.E., Licence D.R., and Charnock-Jones D.S. Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity. Mol Endocrinol 13 (1999) 537-545
6. He H., Venema V.J., Gu X., Venema R.C., Marrero M.B., and Caldwell R.B. Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src. J Biol Chem 274 (1999) 25130-25135
7. Levine R.J., Lam C., Qian C., et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 355 (2006) 992-1005
8. Levine R.J., Maynard S.E., Qian C., et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350 (2004) 672-683
9. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
10. Maynard S.E., Min J.Y., Merchan J., et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111 (2003) 649-658
11. Gougos A., St Jacques S., Greaves A., et al. Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein of endothelial cells, leukemic cells, and syncytiotrophoblasts. Int Immunol 4 (1992) 83-92
12. St Jacques S., Forte M., Lye S.J., and Letarte M. Localization of endoglin, a transforming growth factor-beta binding protein, and of CD44 and integrins in placenta during the first trimester of pregnancy. Biol Reprod 51 (1994) 405-413
13. Bourdeau A., Dumont D.J., and Letarte M. A murine model of hereditary hemorrhagic telangiectasia. J Clin Invest 104 (1999) 1343-1351
14. Toporsian M., Gros R., Kabir M.G., et al. A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia. Circ Res 96 (2005) 684-692
15. Venkatesha S., Toporsian M., Lam C., et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 12 (2006) 642-649
16. Poon L.L., Leung T.N., Lau T.K., and Lo Y.M. Presence of fetal RNA in maternal plasma. Clin Chem 46 (2000) 1832-1834
17. Ng E.K., Tsui N.B., Lau T.K., et al. mRNA of placental origin is readily detectable in maternal plasma. Proc Natl Acad Sci USA 100 (2003) 4748-4753
18. Ng E.K., Leung T.N., Tsui N.B., et al. The concentration of circulating corticotropin-releasing hormone mRNA in maternal plasma is increased in preeclampsia. Clin Chem 49 (2003) 727-731
19. Purwosunu Y., Sekizawa A., Koide K., et al. Cell-free mRNA concentrations of PAI-1 and tPA are increased in the plasma of pregnant women with pre-eclampsia. Clin Chem 53 (2007) 399-404
20. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol 99 (2002) 159-167
21. Martin Jr. J.N., Blake P.G., Perry Jr. K.G., McCaul J.F., Hess L.W., and Martin R.W. The natural history of HELLP syndrome: patterns of disease progression and regression. Am J Obstet Gynecol 164 (1991) 1500-1509 discussion 1509-13
22. Okazaki S., Sekizawa A., Purwosunu Y., Iwasaki M., Farina A., and Okai T. Measurement of mRNA of trophoblast-specific genes in cellular and plasma components of maternal blood. J Med Genet 43 (2006) e47
23. Baker P.N., Krasnow J., Roberts J.M., and Yeo K.T. Elevated serum levels of vascular endothelial growth factor in patients with preeclampsia. Obstet Gynecol 86 (1995) 815-821
24. Hunter A., Aitkenhead M., Caldwell C., McCracken G., Wilson D., and McClure N. Serum levels of vascular endothelial growth factor in preeclamptic and normotensive pregnancy. Hypertension 36 (2000) 965-969
25. McKeeman G.C., Ardill J.E., Caldwell C.M., Hunter A.J., and McClure N. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol 191 (2004) 1240-1246
26. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 280 (2001) C1358-C1366
27. Taylor C.M., Stevens H., Anthony F.W., and Wheeler T. Influence of hypoxia on vascular endothelial growth factor and chorionic gonadotrophin production in the trophoblast-derived cell lines: JEG, JAr and BeWo. Placenta 18 (1997) 451-458
28. Lam C., Lim K.H., and Karumanchi S.A. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension 46 (2005) 1077-1085
29. Lyall F., Greer I.A., Boswell F., and Fleming R. Suppression of serum vascular endothelial growth factor immunoreactivity in normal pregnancy and in pre-eclampsia. Br J Obstet Gynaecol 104 (1997) 223-228
30. Livingston J.C., Chin R., Haddad B., McKinney E.T., Ahokas R., and Sibai B.M. Reductions of vascular endothelial growth factor and placental growth factor concentrations in severe preeclampsia. Am J Obstet Gynecol 183 (2000) 1554-1557
31. Reuvekamp A., Velsing-Aarts F.V., Poulina I.E., Capello J.J., and Duits A.J. Selective deficit of angiogenic growth factors characterises pregnancies complicated by pre-eclampsia. Br J Obstet Gynaecol 106 (1999) 1019-1022
32. Bosio P.M., Wheeler T., Anthony F., Conroy R., O'Herlihy C., and McKenna P. Maternal plasma vascular endothelial growth factor concentrations in normal and hypertensive pregnancies and their relationship to peripheral vascular resistance. Am J Obstet Gynecol 184 (2001) 146-152
33. Shaarawy M., Al-Sokkary F., Sheba M., Wahba O., Kandil H.O., and Abdel-Mohsen I. Angiogenin and vascular endothelial growth factor in pregnancies complicated by preeclampsia. Int J Gynaecol Obstet 88 (2005) 112-117
34. Anthony F.W., Evans P.W., Wheeler T., and Wood P.J. Variation in detection of VEGF in maternal serum by immunoassay and the possible influence of binding proteins. Ann Clin Biochem 34 Pt 3 (1997) 276-280
35. Thadhani R., Mutter W.P., Wolf M., et al. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 89 (2004) 770-775
36. Farina A., Sekizawa A., Sugito Y., et al. Fetal DNA in maternal plasma as a screening variable for preeclampsia. A preliminary nonparametric analysis of detection rate in low-risk nonsymptomatic patients. Prenat Diagn 24 (2004) 83-86
37. Sekizawa A., Farina A., Sugito Y., et al. Proteinuria and hypertension are independent factors affecting fetal DNA values: a retrospective analysis of affected and unaffected patients. Clin Chem 50 (2004) 221-224
38. Sekizawa A., Jimbo M., Saito H., et al. Increased cell-free fetal DNA in plasma of two women with invasive placenta. Clin Chem 48 (2002) 353-354
39. Sekizawa A., Sugito Y., Iwasaki M., et al. Cell-free fetal DNA is increased in plasma of women with hyperemesis gravidarum. Clin Chem 47 (2001) 2164-2165